Literature DB >> 18592251

[Experiences with a centralised national service for autologous serum eyedrops in England].

S Maclennan1, D Hartwig, G Geerling.   

Abstract

The majority of patients with dry eye syndromes respond to conventional treatment aimed at optimising the ocular surface environment. There are some, however, who do not respond adequately to conventional lubricants. The first description of the use of autologous serum as a nutrient tears substitute was published more than 20 years ago. In 1997, NHS Blood and Transplant (NHSBT) developed a reliable and reproducible method for the production of eyedrops derived from autologous serum according to GMP Guidelines. The current cost of a batch of eyedrops (i. e. the product from one donation episode) is approximately 1300 GBP - this covers costs of collection, processing, testing and distribution. One "batch" of eyedrops will last for approximately 5 months if a bottle a day is used. A 6 month shelf life is put on the product and patients keep them in their domestic freezer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18592251     DOI: 10.1007/s00347-008-1753-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  5 in total

1.  The treatment of dry eyes.

Authors:  J P Whitcher
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

2.  Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca.

Authors:  R I Fox; R Chan; J B Michelson; J B Belmont; P E Michelson
Journal:  Arthritis Rheum       Date:  1984-04

3.  Fibronectin in healing rabbit corneal wounds.

Authors:  L S Fujikawa; C S Foster; T J Harrist; J M Lanigan; R B Colvin
Journal:  Lab Invest       Date:  1981-08       Impact factor: 5.662

Review 4.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

5.  Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.

Authors:  B A Noble; R S K Loh; S MacLennan; K Pesudovs; A Reynolds; L R Bridges; J Burr; O Stewart; S Quereshi
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

  5 in total
  4 in total

1.  [On the use of autologous serum eyedrops in Germany : results of a survey among members of the Cornea Section of the German Ophthalmological Society (DOG)].

Authors:  K Kasper; L Godenschweger; D Hartwig; J D Unterlauft; B Seitz; G Geerling
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

2.  [Introduction to the topic: blood products for treatment of diseases of the ocular surface. Voodoo or standard therapy].

Authors:  G Geerling; B Seitz
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

Review 3.  Assessment and management of dry eye disease.

Authors:  R J Buckley
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

Review 4.  Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy.

Authors:  Antonio J Villatoro; Viviana Fernández; Silvia Claros; Cristina Alcoholado; Manuel Cifuentes; Jesús Merayo-Lloves; José A Andrades; José Becerra
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.